Loxo Oncology Inc. (NASDAQ:LOXO) traded down 3.6% during mid-day trading on Thursday . The company traded as low as $24.77 and last traded at $25.62, with a volume of 59,149 shares changing hands. The stock had previously closed at $26.57.

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $36.00 price objective on shares of Loxo Oncology in a report on Monday, April 18th. Citigroup Inc. increased their target price on shares of Loxo Oncology from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, March 16th. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $30.00 target price on shares of Loxo Oncology in a research note on Tuesday, April 19th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Loxo Oncology currently has a consensus rating of “Buy” and an average target price of $29.60.

The firm’s market cap is $500.39 million. The stock has a 50 day moving average of $24.90 and a 200 day moving average of $23.23.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.10. Equities analysts expect that Loxo Oncology Inc. will post ($2.28) EPS for the current fiscal year.

In other news, major shareholder Aisling Capital Iii Lp acquired 232,558 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The shares were bought at an average price of $21.50 per share, with a total value of $4,999,997.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Several hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in shares of Loxo Oncology during the fourth quarter valued at $1,055,000. AWM Investment Company Inc. raised its stake in shares of Loxo Oncology by 40.0% in the fourth quarter. AWM Investment Company Inc. now owns 105,000 shares of the biopharmaceutical company’s stock valued at $2,987,000 after buying an additional 30,000 shares during the last quarter. Finally, Aisling Capital LLC raised its stake in shares of Loxo Oncology by 10.0% in the fourth quarter. Aisling Capital LLC now owns 3,796,362 shares of the biopharmaceutical company’s stock valued at $108,006,000 after buying an additional 343,869 shares during the last quarter.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.